百特醫療 (BAX) 2008 Q4 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Good morning, ladies and gentlemen, and welcome to Baxter International first quarter earnings conference call. (Operator instructions) . I would now like to turn the call over to Ms. Mary Kay Ladone, Vice President, Investor Relations at Baxter International. You may

    各位女士、先生,早安,歡迎參加百特國際第一季財報電話會議。(接線員指示)。現在我想把電話交給百特國際投資人關係副總裁 Mary Kay Ladone 女士。您可以

  • Mary Kay Ladone - VP Investor Relations

    Mary Kay Ladone - VP Investor Relations

  • Thank you, and good morning, everyone and welcome to our Q4, 2008 earnings conference call. Joining me today are Bob Parkinson, CEO and Chairman of Baxter International; and Rob Davis, Chief Financial Officer.

    謝謝,各位早安,歡迎參加我們 2008 年第四季(Q4)財報電話會議。今天與我一同出席的有:百特國際執行長兼董事長 Bob Parkinson,以及財務長 Rob Davis。

  • Before we get started, let me remind you that this presentation, including comments regarding our financial outlook, new product developments, and regulatory matters contain forward-looking statements that involve risks and uncertainties, and of course our actual results could differ materially from our current expectations. Please refer to today's press release and our SEC filings for more detail concerning factors that could cause actual results to differ materially. In addition in today's call, non-GAAP financial measures will be used to help investors understand Baxter's ongoing business performance. A reconciliation of the non-GAAP financial measures being discussed today to the comparable GAAP financial measures is included in our earnings release issued this morning and available on our website. Now I would like to turn the call over to Bob Parkinson.

    在開始之前,先提醒各位,本簡報(包括關於我們的財務展望、新產品開發與法規事項的評論)包含前瞻性陳述,涉及風險與不確定性;當然,我們的實際結果可能與目前預期有重大差異。關於可能導致實際結果與目前預期有重大差異的因素,請參閱今日新聞稿及我們向美國證券交易委員會(SEC)提交的文件以取得更多細節。此外,在今天的電話會議中,將使用非 GAAP 財務衡量指標,以協助投資人了解百特持續性業務表現。今日討論之非 GAAP 財務衡量指標與可比較之 GAAP 財務衡量指標的調節表,已包含於我們今早發布並可於網站取得的財報新聞稿中。現在我想把電話交給 Bob Parkinson。

  • Bob Parkinson - CEO

    Bob Parkinson - CEO

  • Thanks, Mary Kay. Good morning everyone and thanks for calling in this morning. We're pleased today to announce our financial results for the fourth quarter and full year, 2008, and also provide our outlook for 2009. Rob will provide more details in just a few minutes, but let me first start by saying that 2008 was an outstanding year for Baxter, we believe we are very well positioned for 2009 and beyond.

    謝謝你,Mary Kay。各位早安,也謝謝大家今天早上撥冗來電。我們很高興今天公布 2008 年第四季與全年財務結果,並提供 2009 年展望。Rob 會在幾分鐘後提供更多細節,但我先說,2008 年對百特而言是非常出色的一年;我們相信公司已為 2009 年及未來做好非常充分的準備。

  • First, we exceeded all of our financial objectives for the year, achieving record sales, earnings and cash flow despite a very challenging global economic climate that developed particularly late in the year. World wide we succeeded in driving growth through geographic expansion, leveraging the momentum of our existing businesses, while concurrently pursuing selective new business development opportunities and accelerating our investment in research and development to its highest level in the Company's history. Adjusted EPS of $0.91 exceeded guidance for the quarter, and increased 20% versus the prior year. Full year adjusted EPS of $3.38 per share, increased 21%, and exceeded our original full-year EPS guidance range of $3.10 to $3.18 per share. Sales growth for the quarter excluding FX was robust, increasing 9%, which clearly reinforces the value and strength of our diversified business model and illustrates the solid fundamentals underpinning our portfolio.

    首先,我們達成並超越了全年所有財務目標;即使在年末特別惡化、極具挑戰的全球經濟環境下,仍創下銷售、獲利與現金流的歷史新高。在全球範圍內,我們透過地理版圖擴張推動成長,善用既有業務動能,同時尋求具選擇性的新增業務開發機會,並將研發投資加速提升至公司史上最高水準。第四季調整後每股盈餘(Adjusted EPS)為 0.91 美元,高於本季指引,且較去年同期成長 20%。全年調整後每股盈餘為每股 3.38 美元,成長 21%,並超越我們原先全年 EPS 指引區間每股 3.10 至 3.18 美元。若排除匯率(FX)影響,本季銷售成長強勁,增加 9%,這清楚強化了我們多元化商業模式的價值與實力,也顯示我們投資組合背後穩健的基本面。

  • I'm also particularly encouraged with the consistency of our improving margins. Adjusted growth margins in the fourth quarter and full year was approximately 51%, an historic level for the Company. Adjusted operating income as a percentage of sales was 22.6% in the fourth quarter and approximately 22% for the full year, which represents an improvement of over 100 basis points versus 2007. As we look forward beyond 2008 we continue to be enthusiastic about the margin expansion opportunities derived from improved product and business mix, intense focus on pricing opportunities, and disciplined control of manufacturing costs and productivity improvements throughout our global manufacturing footprint. Throughout 2008, each of Baxter's global businesses continued to our -- or contributed to our overall performance financially, operationally, and strategically.

    我也特別受到我們利潤率持續改善的一致性所鼓舞。第四季與全年調整後毛利率約為 51%,為公司歷史性水準。第四季調整後營業利益占銷售比重為 22.6%,全年約為 22%,較 2007 年改善超過 100 個基點。展望 2008 年之後,我們仍對利潤率擴張機會感到振奮,這些機會來自更佳的產品與業務組合、對定價機會的高度聚焦,以及對製造成本的嚴謹控管與在全球製造據點推動生產力提升。2008 年期間,百特各全球事業持續在財務、營運與策略面為我們整體表現作出貢獻。

  • So I would like to take just a moment to highlight some of -- a few of the achievements from across all three businesses. First, starting with medication delivery. We expanded our presence in the global anesthesia market with the continued success of Suprane, augmented by the launch of of Baxter's Sevoflurane in nine new markets across Europe. Our global anesthesia sales totaled more than $450 million in 2008, and grew 10% for the year. I would also like to highlight our nutrition business which was the fastest-growing business within medication delivery in 2008. Annual sales of our nutrition business increased 13% in 2008 and now exceeds $600 million on a global basis primarily as the result of increased demand for our proprietary multi-chamber container outside of the US.

    因此,我想花一點時間重點說明三大事業中一些成果。首先從藥物輸注(medication delivery)開始:我們在全球麻醉市場持續擴大布局,Suprane 持續成功,同時在歐洲九個新市場推出百特的 Sevoflurane。2008 年我們全球麻醉產品銷售總額超過 4.5 億美元,全年成長 10%。我也想特別提到我們的營養業務,這是 2008 年藥物輸注事業中成長最快的業務。營養業務 2008 年全年銷售成長 13%,目前全球銷售已超過 6 億美元,主要是因美國以外市場對我們專有多腔室容器的需求增加。

  • We launched our V-Link Luer-activated device, the first needleless IV connector containing an anti-microbial coating that has been shown to kill 99.9% of specific common pathogens that cause catheter-related bloodstream infections including MRSA or "mersa". We completed a study of 50 patients using Hylenex or pediatric hydration.. Hylenex enables the dispersion and absorption of fluids drugs. The results from this study will be published in 2009. And on the Colleague front, despite some disappointments in 2008, we did continue to make progress, we have now remediated more than 100,000 of the Colleague single-channel pumps, and continue to be in active dialogue with the FDA relative to additional software modifications and. clinical evaluation of pump enhancements and potential changes to complete our current remediation plan. For this reason we have elected not to include revenue related to the US commercialization of Colleague in our 2009 guidance. We do hope to have more details to share with you in the coming months. In addition, we continue to move forward with a number of other initiatives that reflect our continued commitment to our infusion system business.

    我們推出 V-Link 魯爾(Luer)啟動式裝置,這是第一款含抗菌塗層的無針靜脈(IV)連接器,已證實可殺死 99.9% 的特定常見病原體;這些病原體會造成與導管相關的血流感染,包括 MRSA(或稱「mersa」)。我們完成了一項針對 50 名病患使用 Hylenex 進行兒科補液(pediatric hydration)的研究。Hylenex 可促進液體與藥物的擴散與吸收。該研究結果將於 2009 年發表。至於 Colleague 方面,儘管 2008 年有一些令人失望之處,我們仍持續取得進展;目前已完成超過 100,000 台 Colleague 單通道幫浦的改善(remediated),並持續就額外軟體修改、幫浦強化的臨床評估,以及為完成現行改善計畫可能需要的變更,與 FDA 保持積極對話。基於此原因,我們決定在 2009 年指引中不納入與 Colleague 在美國商業化相關的營收。我們希望在未來幾個月能與各位分享更多細節。此外,我們也持續推進多項其他計畫,反映我們對輸注系統業務的持續承諾。

  • In the renal business, Baxter played an important role in supporting the passage of US Medicare reforms that are expected to make peritoneal dialysis a more competitive therapy option in the years ahead. Specifically the provisions eliminated incentives that currently favor the prescribing of hemodialysis and provide reimbursement for pre end-stage renal disease education. Studies have shown that given unbiased objective education on treatment options, about 50% of all patients would chose home therapy versus 8% of patients on PD today. These provisions have already been approved and become effective in 2010 and 2011. Excluding the impact of the Mexico tender, which we spoke of previously, we achieved 7% growth in PD patients in 2008. This was driven by increased penetration in the developed markets and double-digit patient gains in China and the rest of Asia.

    在腎臟事業方面,百特在支持美國 Medicare 改革通過上扮演了重要角色;該改革預期將使腹膜透析(PD)在未來幾年成為更具競爭力的治療選項。具體而言,相關條款取消了目前偏向開立血液透析(hemodialysis)的誘因,並提供末期腎臟病(end-stage renal disease)前期教育的給付。研究顯示,若能在不帶偏見且客觀的治療選項教育下,約 50% 的病患會選擇居家治療,而目前接受 PD 的病患僅約 8%。這些條款已獲核准,並將於 2010 年與 2011 年生效。若排除我們先前提及的墨西哥標案(Mexico tender)影響,2008 年 PD 病患數成長 7%。此成長來自已開發市場滲透率提升,以及中國與亞洲其他地區病患數的兩位數成長。

  • We continue to strengthen our global leadership position and expand geographically as governments, particularly in the developing world, focus on providing increased access to treatment for patients with end-stage renal disease, and we also continued development to expand our leadership in home dialysis therapy with our partner DEKA on a home hemo-dialysis device which progressed well throughout 2008. We have now completed develop of a prototype and expect to begin clinical trials in 2009, leading to an anticipated market launch in 2011. Finally within bioscience, we're very pleased with the continued success of Advate. With annual sales of more than $1.5 billion Advate has now established a leadership position in the US, Europe, Japan, Australia, and an array of other companies. We continue to expand this position, with our industry-leading range of dosage strength, when enables more precise dosing and increased convenience for patients.

    隨著各國政府(特別是開發中國家)著重於提高末期腎臟病患者的治療可近性,我們持續強化全球領導地位並擴大地理布局;同時,我們也與合作夥伴 DEKA 持續開發居家血液透析裝置,以擴大我們在居家透析治療的領導地位,該專案在 2008 年進展良好。我們目前已完成原型機的開發,並預期於 2009 年開始臨床試驗,目標在 2011 年上市。最後,在生物科學(bioscience)方面,我們對 Advate 的持續成功感到非常滿意。Advate 年銷售額超過 15 億美元,已在美國、歐洲、日本、澳洲以及其他多個國家建立領導地位。我們持續擴大此一地位,憑藉業界領先的多種劑量規格範圍,使得劑量更精準並提升病患便利性。

  • Also in the area of hemophilia we've made progress in the development of a recombinant form of von Willebrand factor another protein-critical for clotting for people with von Willebrand disease. von Willebrand disease is the most common hereditary bleeding disorder in both men and women and recently we announced the initiation of a Phase I clinical program. In immune therapy we initiated three Phase III clinical programs with the intent of expanding approved indications for Gammagard Liquid for IG IV. These trials include one evaluating the use of Gammagard Liquid for multi focal motor neuropathy or MFN a rare neurological disorder characterized by progressive limb weakness primarily affecting the upper extremities and another for the treatment of Alzheimer's disease. In addition, we recently announced the start of the Phase III trial combining Gammagard Liquid with Enhanze Halozyme's proprietary drug delivery technology for subcutaneous dosing of IV IG patients with primary immunodeficiencies disorders, Subcutaneous administration of Gammagard Liquid via a single site could allow patients to administer their dose of IG IV once monthly at home.

    同樣在血友病領域,我們在開發重組型 von Willebrand 因子方面取得進展;這是另一種對凝血至關重要的蛋白質,適用於 von Willebrand 氏病患者。von Willebrand 氏病是男女皆可能罹患、最常見的遺傳性出血性疾病;我們近期宣布啟動第一期(Phase I)臨床計畫。在免疫治療方面,我們啟動三項第三期(Phase III)臨床計畫,目標是擴大 Gammagard Liquid 用於靜脈注射免疫球蛋白(IG IV)的核准適應症。這些試驗包括:一項評估 Gammagard Liquid 用於多灶性運動神經病變(multi focal motor neuropathy,或 MFN)—這是一種以進行性肢體無力為特徵、主要影響上肢的罕見神經疾病;以及另一項用於治療阿茲海默症。此外,我們近期也宣布啟動第三期試驗,將 Gammagard Liquid 與 Enhanze(Halozyme 的專有藥物傳輸技術)結合,以皮下注射方式為原本接受 IV IG 的原發性免疫缺乏症患者給藥。透過單一注射部位以皮下方式施打 Gammagard Liquid,可能讓病患在家中每月一次自行施打其 IG IV 劑量。

  • In regenerative medicine we continue to augment our biosurgery portfolio with the launch of ARTISS, the first and only slow setting fibrin sealant indicated for use in adhering skin grafts in burn patients. And, with the launch of Gelfoam Plus hemostatic device for use in surgical procedures, we also advanced several program with our partner Kuros BioSurgery AG, focused on the development and commercialization of a portfolio of hard and soft tissue repair products which, if successful, will allow us to enter the fast-growing Orthobiologics market. And finally, in the vaccine business we advanced both our pandemic and seasonal influenza programs. We are currently conducting two Phase III clinical trials utilizing our seasonal influenza vaccine candidate and we recently received a positive opinion in Europe for our candidate pandemic vaccine which provides us with the license and the ability to market the vaccine in the event of a pandemic. So all in all it has been a very productive year. Just to briefly summarize. Consistent with our strategic priorities, we accelerated on an adjusted bases overall R&D spending in 2008 by 20% to almost $900 million, a record level for the Company. We received approval for or launched an array of new products during the year initiated eight major Phase III medical trials, advanced numerous early stage internal programs and established new partnerships with companies like Nektar, Nycomed and [Inocalm] -- just to name a few.

    在再生醫學方面,我們持續透過推出 ARTISS 來擴充我們的生物外科產品組合;ARTISS 是第一且唯一一款慢凝固纖維蛋白封合劑,適用於燒傷病患皮膚移植片的黏附使用。此外,隨著推出可用於外科手術的 Gelfoam Plus 止血裝置,我們也與合作夥伴 Kuros BioSurgery AG 推進了多項計畫,聚焦於硬組織與軟組織修復產品組合的開發與商業化;若成功,將使我們得以進入快速成長的骨科生物製劑(Orthobiologics)市場。最後,在疫苗業務方面,我們同時推進了大流行與季節性流感計畫。我們目前正進行兩項使用季節性流感疫苗候選產品的第三期臨床試驗,且近期在歐洲就我們的大流行疫苗候選產品獲得正面意見,使我們取得許可,並在發生大流行時具備上市銷售該疫苗的能力。總而言之,這是非常有成效的一年。簡要總結一下:依循我們的策略優先事項,我們在 2008 年以調整後口徑將整體研發支出加速提高 20%,達到接近 9 億美元,創公司新高。我們在年度內獲准或推出一系列新產品,啟動八項重大第三期醫療試驗,推進多項早期內部計畫,並與 Nektar、Nycomed 以及 [Inocalm] 等公司建立新的合作夥伴關係——僅舉幾例。

  • In 2009 and beyond given our strong foundation and financial flexibility, we'll continue to advance our product pipeline and do so with disciplined project management, and increased productivity while balancing the pipeline with both short and long-term opportunities, and always with a continued focus on value creation. So with that let me turn the call over to Rob for a more detailed discussion on our Q4 results, also our outlook for 2009 and when Rob concludes his commentary, I have just a few additional comments in respect to this year before we then open up the call for q&a. -- so Rob?

    在 2009 年及其後,鑑於我們堅實的基礎與財務彈性,我們將持續推進產品研發管線,並以嚴謹的專案管理與更高的生產力來執行,同時在短期與長期機會之間平衡管線,並始終聚焦於價值創造。那麼接下來我把電話交給 Rob,請他更詳細說明我們第四季的業績,以及我們對 2009 年的展望;在 Rob 結束他的說明後,我還有幾點關於今年的補充意見,之後我們再開放 q&a。——那麼 Rob?

  • Rob Davis - CFO

    Rob Davis - CFO

  • Thanks, Bob. And good morning, everyone. As Bob mentioned, we are very pleased with our fourth quarter results, which include a strong organic sales growth, continued margin expansion, and earnings that exceeded our guidance. We're also very pleased with our ability to generate strong cash flow, and to deliver significant value to our shareholders through our disciplined Cap allocation strategy. Let me briefly walk you through the P&L by line for Q4 before providing you with the details on our financial outlook for 2009. Starting with sales, our reported sales in the quarter totaled approximately $3.1 billion, and increased to 4%. Excluding foreign currency, sales growth of 9% exceeded our guidance of approximately 7%, and was driven by better than expected recompetent sales robust growth across all major product categories within bioscience, and strong growth in medication delivery, particularly in the global injectables business. Sales growth in the US was 6%, the highest quarterly growth of the year. This was a result of consistent double-digit sales growth for bioscience, and an acceleration of growth in the medication delivery business. International sales increased 3% on a reported basis, and excluding foreign currency sales growth was 10% with strong growth across all regions in most major product categories.

    謝謝你,Bob。各位早安。如 Bob 所提到的,我們對第四季的結果非常滿意,其中包括強勁的有機銷售成長、持續的毛利率擴張,以及超出我們指引的盈餘表現。我們也很高興能夠產生強勁的現金流,並透過我們嚴謹的資本配置(Cap allocation)策略,為股東創造顯著價值。在向各位提供 2009 年財務展望細節之前,我先按損益表(P&L)各項目簡要帶各位回顧第四季。從銷售額開始,本季申報銷售額合計約 31 億美元,成長 4%。若排除外幣影響,銷售成長 9% 高於我們約 7% 的指引,主要由優於預期的 recompetent 銷售、生命科學(bioscience)各主要產品類別的強勁成長,以及藥物輸送(medication delivery)業務的強勁成長所帶動,尤其是全球注射劑(injectables)業務。美國銷售成長 6%,為全年最高的單季成長,原因是生命科學持續維持兩位數銷售成長,以及藥物輸送業務成長加速。國際銷售以申報口徑成長 3%;若排除外幣影響,銷售成長為 10%,且在多數主要產品類別上,各區域均呈現強勁成長。

  • Year to date, sales increase 10%, and sales growth, excluding foreign currency, was 6%. I would also like to remind you that in 2008, we annualized several items that created difficult growth comparisons for us over the past year or so, like the transfusion therapies divestiture, BeneFIX, Propofol and the Mexican PD tender, which all in total impacted our 2008 full-year sales growth by approximately two to three percentage points. In terms of individual business performance, let me start with medication delivery, which had fourth quarter sales totaling approximately $1.2 billion, an increase of 2% on a reported basis. Excluding foreign currency, medication delivery sales accelerated and increased 7%, which on an organic basis represented the highest quarterly growth rate of the year. This acceleration was primarily driven by improved growth in the US, where sales increased 5% driven by solid performance of IV therapy and anesthesia products, and positive growth in the global injectables business for the first time this year.

    年初至今,銷售額成長 10%;若排除外幣影響,銷售成長為 6%。我也想提醒各位,在 2008 年,我們將若干項目年化處理,導致過去一年左右的成長比較基期較為艱難,例如輸血治療(transfusion therapies)業務的處分、BeneFIX、Propofol 以及墨西哥 PD 標案(tender)等;上述因素合計使我們 2008 年全年銷售成長約減少 2 至 3 個百分點。就各業務表現而言,我先從藥物輸送開始:第四季銷售額合計約 12 億美元,以申報口徑成長 2%。若排除外幣影響,藥物輸送銷售加速成長至 7%;以有機口徑來看,這是全年最高的單季成長率。此一加速主要由美國市場成長改善所帶動,美國銷售成長 5%,來自靜脈輸液(IV)治療與麻醉產品的穩健表現,以及全球注射劑業務在今年首次轉為正成長。

  • International sales in medication delivery declined 1% on a reported basis, but excluding foreign currency, sales increased 8%. For the full year, medication delivery sales of $4.6 billion, increased 8%, and excluding foreign currency, sales were up 5%, exceeding our full-year guidance of approximately 4% of growth. Turning to the product categories, IV therapy sales in the fourth quarter totaled $393 million and increased 1%. Excluding foreign currency, sales increased 7% and continue to be driven by solid demand for our IV solutions globally, US pricing improvements, and strong growth in our nutrition business. Infusion system sales totaled $222 million in the quarter and declined 6%. Excluding foreign currencies, sales declined 2%. As Colleague remediation revenues were more than offset by lower sales of access sets. Sales of global injectables increased 8% to $420 million, as a result of strong growth in the US. US sales increased 11%.

    藥物輸送的國際銷售以申報口徑下滑 1%,但若排除外幣影響,銷售成長 8%。全年而言,藥物輸送銷售額為 46 億美元,成長 8%;若排除外幣影響,銷售成長 5%,高於我們全年約 4% 成長的指引。接著看產品類別:第四季 IV 治療銷售額為 3.93 億美元,成長 1%。若排除外幣影響,銷售成長 7%,持續由我們全球 IV 溶液的穩健需求、美國價格改善,以及營養(nutrition)業務的強勁成長所帶動。輸注系統(infusion system)本季銷售額為 2.22 億美元,下滑 6%;若排除外幣影響,下滑 2%。Colleague 補救(remediation)收入被通路(access)套件銷售下滑所抵銷。全球注射劑銷售成長 8% 至 4.20 億美元,主要因美國市場強勁成長;美國銷售成長 11%。

  • The strongest growth of the year as the negative comparison for Heparin was more than offset by mid-teens growth in our pharma partnering business, and strong growth of certain premixed and multi-sourced generic drugs. The international growth was once again the result of solid growth in our pharmacy compounding business. And finally, anesthesia sales totaled $131 million and increased 4%, excluding foreign currency, sales increased 7%, driven by the global penetration of Suprane, and growth of Sevoflurane. Moving on to renal. Fourth quarter sales totaled $557 million, and declined 7% on a reported basis. Adjusting for foreign currency, sales declined 3%. This was the continued result of a decline in hemodialysis sales and the difficult comparison created by the loss of the Mexican PD Tender in the first quarter of 2008. Renal sales for the full year, totaled $2.3 billion, an increase of 3%, with currency contributing five points to this growth, excluding foreign currency, therefore, sales declined by 2%.

    這是全年最強勁的成長,因為肝素(Heparin)的負向比較影響,已被我們製藥合作(pharma partnering)業務的約中十位數(mid-teens)成長,以及部分預混(premixed)與多來源(multi-sourced)學名藥的強勁成長所抵銷。國際成長則再次來自我們藥局調劑(pharmacy compounding)業務的穩健成長。最後,麻醉產品銷售額為 1.31 億美元,成長 4%;若排除外幣影響,銷售成長 7%,主要由 Suprane 的全球滲透率提升,以及 Sevoflurane 的成長所帶動。接著談腎臟(renal)業務:第四季銷售額為 5.57 億美元,以申報口徑下滑 7%;若調整外幣影響,銷售下滑 3%。這仍是因血液透析(hemodialysis)銷售下滑,以及 2008 年第一季失去墨西哥 PD 標案所造成的艱難比較基期。全年腎臟業務銷售額為 23 億美元,成長 3%;其中匯率對成長貢獻 5 個百分點,因此若排除外幣影響,銷售反而下滑 2%。

  • Globally PD sales totaled $458 million in the fourth quarter, and declined 5% on a reported basis. Excluding foreign currency, global PD sales were down 1%. Excluding both the impact of the loss tender in Mexico and foreign currency, international PD sales were up approximately 4%, and global PD sales also increased 4%. This growth is due to the expanded use of peritoneal dialysis in many developed and emerging markets around the world. In the US we continue to see positive PD patient growth which resulted in a 7% increase in US PD sales. Hemodialysis sales in the fourth quarter of $99 million were down 18%, and excluding foreign currency, sales declined by 12%.

    全球 PD(腹膜透析)第四季銷售額為 4.58 億美元,以申報口徑下滑 5%。若排除外幣影響,全球 PD 銷售下滑 1%。若同時排除墨西哥失去標案與外幣影響,國際 PD 銷售約成長 4%,全球 PD 銷售亦成長 4%。此一成長來自全球多個已開發與新興市場對腹膜透析使用的擴大。在美國,我們持續看到 PD 病患人數的正向成長,使美國 PD 銷售成長 7%。第四季血液透析銷售額為 9,900 萬美元,下滑 18%;若排除外幣影響,銷售下滑 12%。

  • Turning now to bioscience. Bioscience sales totaled approximately $1.4 billion and increased 12%. Excluding foreign currency, bioscience sales increased 17% with double-digit growth across all major product categories. For the full year, bioscience sales were 16% to $5.3 billion. Excluding currency, sales increased 13%, which exceeded our expectation of more than 10% growth. Recombinant sales in the quarter of $506 million, increased 9% on a reported basis and were up 14% excluding the impact of foreign currency. As Bob mentioned earlier, Advate sales of more than $1.5 billion for the full year,exceeded our original expectations. While Advate conversion in Europe remained over 90%, international sales were still robust, and increased 20% for the quarter on a cost of currency basis.. US recombinant sales increased 7%, and conversion to Advate continues, in fact we ended the year with US conversion of more than 60%, compared to conversion of just over 50% in the US last year.

    接著談生命科學(bioscience)。生命科學銷售額約 14 億美元,成長 12%。若排除外幣影響,生命科學銷售成長 17%,且所有主要產品類別均呈現兩位數成長。全年生命科學銷售成長 16% 至 53 億美元;若排除匯率影響,銷售成長 13%,高於我們原先預期的超過 10% 成長。重組(recombinant)產品本季銷售額為 5.06 億美元,以申報口徑成長 9%,若排除外幣影響則成長 14%。如 Bob 先前提到,Advate 全年銷售超過 15 億美元,超出我們原先預期。儘管歐洲 Advate 轉換率仍維持在 90% 以上,國際銷售依然強勁,且以固定匯率口徑本季成長 20%。美國重組產品銷售成長 7%,且向 Advate 的轉換持續進行;事實上,我們年底時美國轉換率已超過 60%,相較去年美國轉換率僅略高於 50%。

  • Turning to the plasma business. In the quarter, plasma protein sales of $330 million increased 10%, excluding the impact of foreign currency, plasma protein sales increased 12%. Performance continues to be driven by strong demand for plasma derived factor VIII, Albumin and ARALAST, as well as improved pricing. US plasma protein sales increased 18% while international sales increased 5% on a reported basis or 9% on a constant currency basis. Antibody therapy sales increased 10% to $309 million in the quarter and excluding foreign currency, antibody therapy sales grew 14% driven by strong demand for Gammagard Liquid and pricing improvements. Sales in the regenerative medicine business totaled $101 million and increased 6%. Growth, excluding foreign currency, was 12% in the quarter as a result of strong growth of both FloSeal, and CoSeal. Finally revenues in the other category totaled $113 million and included the large vaccine order of approximately $50 million that we discussed with you last quarter.

    接著談血漿業務。本季血漿蛋白銷售額為3.30億美元,成長10%;若排除外幣影響,血漿蛋白銷售成長12%。業績持續受血漿來源第VIII因子、白蛋白(Albumin)與ARALAST的強勁需求,以及定價改善所帶動。美國血漿蛋白銷售成長18%,而國際銷售按報告基礎成長5%,按固定匯率基礎成長9%。本季抗體治療銷售成長10%至3.09億美元;若排除外幣影響,抗體治療銷售成長14%,主要由Gammagard Liquid的強勁需求與定價改善所驅動。再生醫學業務銷售合計1.01億美元,成長6%。若排除外幣影響,本季成長為12%,主要來自FloSeal與CoSeal的強勁成長。最後,其他類別營收合計1.13億美元,其中包含我們在上季與各位討論過、約5,000萬美元的大型疫苗訂單。

  • Now, turning to the rest of the P&L and starting with gross margin. Adjusted gross margin in the fourth quarter of 51.2%, improved sequentially by 60 basis points, and improved year-over-year by 180 basis points. This margin expansion is the result of favorable foreign exchange, improved business and product mix, pricing improvements across multiple businesses and manufacturing efficiencies. For the full year, I'm pleased to report that our gross margin of 50.7% improved 170 basis points versus the 49% we achieved in 2007, And, as Bob pointed out earlier, we believe we have further margin-expansion opportunities over our long-range plan. Turning to SG&A. SG&A of $674 million in the quarter increased 3% compared to the prior year. Excluding foreign currency, SG&A increased in mid-single digits. SG&A as a percentage of sales was 21.5%, reflecting a 20 basis point reduction versus the prior year. For the full year, SG&A increased 9% with foreign currency contributing approximately three points of growth.

    接下來看損益表(P&L)的其餘部分,先從毛利率開始。第四季調整後毛利率為51.2%,較前一季提升60個基點,較去年同期提升180個基點。此毛利率擴張來自有利的外匯因素、業務與產品組合改善、多項業務的定價改善,以及製造效率提升。就全年而言,我很高興報告我們的毛利率為50.7%,較2007年達成的49%提升170個基點。而且,如Bob先前所指出,我們相信在長期計畫期間仍有進一步擴張毛利率的機會。接著看SG&A。第四季SG&A為6.74億美元,較去年同期增加3%。若排除外幣影響,SG&A以中個位數成長。SG&A占銷售比重為21.5%,較去年同期下降20個基點。就全年而言,SG&A增加9%,其中外幣約貢獻3個百分點的成長。

  • R&D spending of $219 million increased 6%, and excluding currency, R&D grew in the high single digits. For the full year, R&D spending of $849 million increased 20%. This growth is the result of investments we are making across all three businesses, particularly in many of the programs that Bob mentioned earlier in his opening comments. Interest expense was $14 million, compared to $12 million last year, and other expense was $1 million in the quarter, compared to $4 million last year. Our tax rate in the fourth quarter of 17.3% was slightly lower than our guidance and reflected the impact of the R&D tax credit as we discussed with your last quarter as well as adjustments to valuation allowances. Excluding these items, our operational tax rate remains at approximately 19%. Finally, as previously mentioned, adjusted EPS in the fourth quarter was $0.91, an increase of 20%, and adjusted EPS for the full year of $3.38, increased 21%. Turning to cash flow, we had another very strong year. Excluding the $240 million pension contribution in the fourth quarter, cash flow from operations for 2008 totaled more than $2.7 billion. This represents more than a $400 million improvement over the $2.3 billion of cash flow reported last year, and exceeded our original cash flow guidance of $2.5 billion. Including the outflow related to pension contributions, cash flow from operations totaled $2.5 billion, an improvement of more than $200 million versus the prior year.

    研發(R&D)支出為2.19億美元,增加6%;若排除匯率影響,研發以高個位數成長。全年研發支出為8.49億美元,增加20%。此成長源自我們在三大業務的投資,特別是Bob在開場致詞中提到的多項計畫。利息費用為1,400萬美元,去年為1,200萬美元;本季其他費用為100萬美元,去年為400萬美元。第四季稅率為17.3%,略低於我們的指引,反映了如同我們上季與各位討論的研發稅額抵減(R&D tax credit)影響,以及對估值備抵(valuation allowances)的調整。排除這些項目後,我們的營運稅率仍約為19%。最後,如先前所提,第四季調整後EPS為0.91美元,增加20%;全年調整後EPS為3.38美元,增加21%。接著談現金流,我們又度過了非常強勁的一年。若排除第四季2.40億美元的退休金提撥,2008年營運活動現金流合計超過27億美元。這較去年報告的23億美元現金流改善超過4億美元,並高於我們原先25億美元的現金流指引。若包含退休金提撥相關的現金流出,營運活動現金流合計為25億美元,較前一年改善超過2億美元。

  • Our total DSO, which ended the year at 50.6 days, improved five days versus last quarter and is approximately three days lower than last year. Inventory turns of 2.5 turns were also better than last quarter. and were flat to last year. Capital expenditures for the year totaled $954 million as we continue to invest in appropriate capacity across our businesses to support our future growth. And lastly, as we commented on in this morning's press release, during 2008, we paid dividends totals approximately $550 million and repurchased 32 million shares of common stock for approximately $2 billion. On a net basis, this amounts to repurchases of 18 million shares or $1.4 billion, which exceeded our commitment of $1 billion for the year. Overall, I'm particularly pleased with our ongoing ability to generate strong cash flows. We continue to return significant value to shareholders as a result of our improved financial flexibility, capital allocation strategy, and disciplined financial management, while accelerating investments in R&D both internally and through selective business development activities that will position us well for future growth.

    我們的總DSO(應收帳款週轉天數)年末為50.6天,較上季改善5天,且較去年約低3天。存貨週轉率為2.5次,也優於上季,且與去年持平。全年資本支出合計9.54億美元,我們持續在各項業務投資適當產能,以支持未來成長。最後,如我們在今早新聞稿中所提,2008年我們支付股利合計約5.50億美元,並以約20億美元回購3,200萬股普通股。以淨額計算,相當於回購1,800萬股或14億美元,超過我們全年10億美元的承諾。整體而言,我對我們持續創造強勁現金流的能力特別滿意。憑藉更佳的財務彈性、資本配置策略與嚴謹的財務管理,我們持續為股東帶來可觀價值,同時加速研發投資(包含內部投入與透過選擇性的業務開發活動),使我們在未來成長上具備良好定位。

  • Finally, let me conclude my comments this morning by providing our financial outlook and guidance for 2009. As you saw in the press release, we expect earnings of $3.70 to $3.78 per diluted share. This guidance reflects a potential modest impact of sales due to the uncertainty of the global macro environment, continued expansion of gross and operating margins, select investments, marketing and promotional activities to support our growth going forward, and increased R&D spending. More specifically, we expect full-year sales growth excluding the impact of foreign exchange of approximately 7%. We expect our reported sales growth to be approximately flat to 2008, which does assume current exchange rates.

    最後,讓我以提供我們2009年的財務展望與指引來結束今早的評論。如各位在新聞稿中所見,我們預期稀釋後每股盈餘為3.70至3.78美元。此指引反映:在全球總體環境不確定性下,銷售可能受到溫和影響;毛利率與營業利益率持續擴張;為支持未來成長而進行的選擇性投資、行銷與推廣活動;以及研發支出增加。更具體而言,我們預期全年銷售(排除外匯影響)約成長7%。我們預期按報告基礎的銷售成長相較2008年約持平,這是假設目前匯率水準。

  • For the full year, we expect gross profit as a percentage of sales to improve by more than 150 basis points, reflecting continued expansion in bioscience, improved profitability in medication delivery and our core PD business, and a benefit from foreign exchange. We expect annual R&D growth in low single digits, given that more than 40% is outside the US; however, this growth is dampened by the stronger US dollar. Therefore, on a constant currency basis, R&D is increasing approximately 10%. We expect SG&A to decline in the low single digits. However, this growth rate is also impacted by a strong US dollar and on a cost of currency basis, SG&A would increase in low to mid-single digits. We expect a tightly manage general and administrative expenses, especially in light of the current environment, while investing in marketing and promotional activities to support the growth of our higher-returning, and higher-growing products. We expect to continue our trend of year-over-year operating margin improvement in 2009 with an improvement of approximately 200 basis points to approximately 24%. We expect interest expense of between 90 to $100 million, and other expense to total approximately $60 million. We expect our tax rate to approximate 18.5 to 19%, and finally, we expect a full-year average share count of 615 to 620 million shares as a result of our share repurchase activities. From a cash flow perspective, we expect cash flow from operations to exceed $2.6 billion, and capital expenditures to total approximately $1 billion.

    就全年而言,我們預期毛利占銷售比重將提升超過150個基點,反映生物科學持續擴張、藥物輸送與核心PD業務獲利能力改善,以及外匯帶來的助益。我們預期全年研發成長為低個位數,因為超過40%的研發支出在美國以外;然而,較強勢的美元會抑制此成長。因此,以固定匯率基礎計算,研發約增加10%。我們預期SG&A將以低個位數下降。然而,此成長率同樣受到強勢美元影響;若以固定匯率成本基礎計算,SG&A將以低至中個位數成長。我們預期將嚴格管理一般與行政費用,特別是在目前環境下,同時投資於行銷與推廣活動,以支持我們報酬率較高、成長較快的產品成長。我們預期在2009年延續營業利益率逐年改善的趨勢,約提升200個基點至約24%。我們預期利息費用介於9,000萬至1億美元,其他費用合計約6,000萬美元。我們預期稅率約為18.5%至19%;最後,因股票回購活動,我們預期全年平均流通股數為6.15億至6.20億股。就現金流而言,我們預期營運活動現金流將超過26億美元,資本支出合計約10億美元。

  • Now, to expand on the sales assumptions for each of the three businesses. For the full year, 2009, we expect renal sales, excluding the impact of foreign currency, to increase in the range of 4 to 6%. This is the result of solid single-digit growth in PD, and flat to declining HD sales. For medication delivery, we expect sales, excluding foreign currency to also grow in the 4 to 6% range. This will be driven by several factors. First, at constant rates, we expect anesthesia to grow in low double digits,due to the demand for Suprane and additional market launches of Sevoflurane. Second, we expect the IV therapy and global injectables business to grow in mid-single digits, and lastly, we expect infusion systems sales to be flat due to lower Colleague remediation revenues year-over-year. Finally, for the bioscience growth, we expect sales growth excluding foreign currency, to once again exceed 10% driven by strong growth across the portfolio.

    現在,進一步說明三大業務各自的銷售假設。就2009年全年而言,我們預期腎臟業務銷售(排除外幣影響)將成長4%至6%。這主要來自PD的穩健個位數成長,以及HD銷售持平至下滑。就藥物輸送而言,我們預期銷售(排除外幣影響)也將成長4%至6%。這將由多項因素帶動。第一,以固定匯率計算,我們預期麻醉產品將以低雙位數成長,主要因Suprane需求以及Sevoflurane的額外市場上市。第二,我們預期IV治療與全球注射劑業務將以中個位數成長;最後,我們預期輸注系統銷售將持平,因Colleague補救(remediation)營收較去年同期下降。最後,就生物科學成長而言,我們預期銷售成長(排除外幣影響)將再次超過10%,由產品組合全面的強勁成長所驅動。

  • First, we expect recombinant sales growth in high single digits. Second, we expect plasma protein and anti-body therapy sales to grow in mid-teens. Third, we expect the regenerative medicine business to again grow in mid-teens, and finally, we expect the other category, which includes our vaccines business to grow in mid-single digits. For the first quarter, as we mentioned in our press release, we expect earnings per diluted share of $0.80 to $0.82, and sales growth, excluding the impact of foreign currency of approximately 7%. Based on current foreign exchange rates, we expect our reported sales in the first quarter to be approximately flat to the first quarter of the 2008. In summary, our 2009 guidance reflects the ongoing operational strength of our businesses, and ability to deliver sustainable growth. It is aligned with our long-range strategic and financial objectives Although we are operating in a volatile and challenging macro environment, the potential effects of which continue to evolve, we remain focused on delivering growth and making appropriate investments for the future. Now I would like to turn the call back to Bob.

    第一,我們預期重組產品銷售將以高個位數成長。第二,我們預期血漿蛋白與抗體療法銷售將以十位數中段成長。第三,我們預期再生醫學業務將再次以十位數中段成長;最後,我們預期其他類別(包含我們的疫苗業務)將以中個位數成長。就第一季而言,如同我們在新聞稿中提到的,我們預期稀釋後每股盈餘為 0.80 至 0.82 美元,且在排除外幣影響後,銷售成長約為 7%。以目前匯率推估,我們預期第一季的報告銷售額相較於 2008 年第一季約持平。總結而言,我們的 2009 年指引反映了我們各項業務持續的營運實力,以及交付可持續成長的能力。這與我們的長期策略與財務目標一致。儘管我們正處於波動且具挑戰性的總體環境中,其潛在影響仍在演變,我們仍專注於推動成長並為未來進行適當投資。現在我想把電話交回給 Bob。

  • Bob Parkinson - CEO

    Bob Parkinson - CEO

  • Thanks, Rob, before we open up the call to q&a, I would just like to make a few closing comments. Clearly, 2008 was a very successful year for Baxter, financially, operationally, and strategically. And while we're certainly not without challenges, we believe our company is very well positioned for 2009, even in today's challenging global macro environment. The progress that we have made over the last several years to improve the quality of our balance sheet and financial performance will provide flexibility and yield great benefits in the coming months and years. The global economy will continue to struggle for the foreseeable future. The companies in many industries are faced with unprecedented and economic challenges.

    謝謝你,Rob。在我們開放問答之前,我想再做幾點結語。很明顯地,2008 年對 Baxter 而言是非常成功的一年,無論在財務、營運或策略面皆然。雖然我們當然也面臨一些挑戰,但我們相信即使在當前充滿挑戰的全球總體環境下,公司在 2009 年仍具備非常良好的定位。過去幾年我們在提升資產負債表品質與財務表現方面所取得的進展,將提供彈性,並在未來數月與數年帶來重大效益。可預見的未來,全球經濟仍將持續艱困。許多產業的公司正面臨前所未有的經濟挑戰。

  • While no company including Baxter is completely immune to potential impacts, given the medically necessary nature of our products, our diversified healthcare model and strong market positions, we're confident in our ability to drive improved performance and grow even in this uncertain environment. Our 2009 outlook is aligned with the solid underlying fundamentals we see in the markets in which we operate, and we remain committed to driving growth while investing in innovation and business-development activities to position us in the future. We look forward to seeing many of you at our investor conference on September 16th of this year in Chicago. At that time we'll provide more incite in to a number of our R&D programs in all of our businesses and will also provide an longer-term outlook on the financial performance of the Company with particular focus on strategic business segments that are critical to our future. In the meantime, we begin 2009 well positioned for continued success. With that we will open up the call for q&a.

    雖然沒有任何公司(包括 Baxter)能完全免於潛在衝擊,但鑑於我們產品的醫療必要性、我們多元化的醫療保健商業模式以及強勁的市場地位,我們對於在此不確定環境中仍能推動績效改善並持續成長充滿信心。我們對 2009 年的展望與我們在所營運市場中所見到的穩健基本面一致;同時,我們仍致力於在推動成長的同時,投資於創新與業務開發活動,以利未來布局。我們期待在今年 9 月 16 日於芝加哥舉行的投資人會議上與各位中的許多人見面。屆時我們將就各項業務中的多個研發計畫提供更多洞見,並就公司財務表現提供更長期的展望,特別聚焦於對我們未來至關重要的策略性業務區隔。在此期間,我們以良好態勢展開 2009 年,並已為持續成功做好準備。接下來我們將開放問答。

  • Operator

    Operator

  • Thank you. We will now begin the question-and-answer session. (Operator instructions) . Our first question comes from MIke Weinstein of JPMorgan.

    謝謝。我們現在開始問答環節。(接線員指示)。我們的第一個問題來自 JPMorgan 的 MIke Weinstein。

  • Mike Weinstein - Analyst

    Mike Weinstein - Analyst

  • Good morning, congratulations on another good quarter. Let me start by asking a few financial questions that would probably be helpful. I would say, one, that with the 2009 guidance, if you could -- I think it would be helpful for everybody if you talked a little bit about the gross margin drivers, you can calling for more than 150 basis points of improvement at the end of 2009. I can add commentary as the drivers behind that would probably be helpful for everybody. Two, the shares outstanding guidance seems to imply about 550 million of net repurchases based on where the stock is at today. Is that right? And third a billion dollars in CapEx in 2009 is higher than what we were modeling. We could like to get some insights into that. Thanks.

    早安,恭喜你們又交出一個好季度。我先問幾個可能會有幫助的財務問題。第一,關於 2009 年指引,如果你們可以——我想如果你們稍微談一下毛利率的驅動因素,對大家會很有幫助;你們預期到 2009 年底毛利率改善超過 150 個基點。若能補充一下背後的驅動因素,應該會對大家很有幫助。第二,流通股數指引看起來意味著以目前股價計算,淨回購約 5.5 億美元。是這樣嗎?第三,2009 年 10 億美元的資本支出高於我們的模型預估。我們想了解一些相關洞見。謝謝。

  • Bob Parkinson - CEO

    Bob Parkinson - CEO

  • Okay. Thanks, Mike. Let me start with the gross margin discussion and Rob can think a little bit responding to the buy-back question and CapEx. You know, as we discussed previously, there's a number of factors that give us a basis of optimism, I think in terms of continued gross margin expansion going forward. It starts with what I would call business mix as you listened to Rob's detail on guidance for next year, clearly our bioscience business is projected to grow at a faster rate than the other businesses. As you know it is a higher-margin business, and so that is a continued contributor to gross margin expansion.

    好的。謝謝你,Mike。我先從毛利率的討論開始,Rob 也可以想一下如何回應回購與資本支出(CapEx)問題。你知道,如同我們先前討論過的,有多項因素讓我們對未來毛利率持續擴張抱持樂觀。我認為首先是所謂的業務組合;如同你聽到 Rob 對明年指引的細節,很明顯我們的生物科學業務預期將以高於其他業務的速度成長。你也知道那是毛利率較高的業務,因此會持續貢獻毛利率擴張。

  • Having said that, within each of our businesses, particular business units that have higher gross margins, are growing at a faster rate, we highlighted in medication delivery, for example, the growth year to year, '08, versus '07 of our anesthesia business, and our nutritionals business both of which have higher gross margins, than medication delivery overall and again for '09 and we are projecting these business units to grow at a faster rate than medication delivery, so those are examples of business units that are higher margins growing at a faster rate.. So again, business mix lead by bioscience, business unit mix within the various businesses, all of our higher growth vehicles tend to be -- these are units or businesses that are higher gross margins. Of course, I think the hallmark of our company is our focus on manufacturing efficiencies, yield improvements in our bioscience business, value-improvement programs, medication delivery, renal and so on, and we continue to pursue manufacturing efficiencies in our global manufacturing footprint with a passion.

    話雖如此,在我們各項業務之內,毛利率較高的特定事業單位成長速度也更快。我們以藥物輸送為例,強調了 2008 年相較 2007 年,我們的麻醉業務與營養品業務的年增成長;這兩者的毛利率都高於整體藥物輸送業務。而在 2009 年,我們也預期這些事業單位的成長速度將高於藥物輸送,因此這些就是毛利率較高且成長更快的事業單位例子。再者,由生物科學帶動的業務組合、以及各業務內部的事業單位組合,我們所有高成長引擎往往——這些單位或業務本身就具有較高毛利率。當然,我認為我們公司的標誌在於專注於製造效率、生物科學業務的良率提升、價值改善計畫(value-improvement programs)、藥物輸送、腎臟等領域;我們也持續以高度投入的態度,在全球製造版圖中追求製造效率。

  • The final thing I would say, Mike, is our focus on price, and we are pursuing price aggressively in those businesses or business segments where we think opportunity exists. We're all aware of the pricing opportunities that continue to exist within plasma proteins, but our pricing improvement story is actually much broader than that, and a good example of that, again, being our core IV business in the US, we're experiencing price improvements to a greater degree than we have in years. So those are -- those are really the primary drivers for gross margin expansion. I don't know if you want to add anything to that, Rob, before we move on to the other two pieces of Mike's question.

    最後我想說的是,Mike,我們對價格的重視;在我們認為存在機會的業務或業務區隔中,我們正積極推動價格。我們都知道血漿蛋白領域仍存在的定價機會,但我們的價格改善故事其實遠不只如此;一個很好的例子是我們在美國的核心 IV 業務,我們正經歷比多年來更顯著的價格改善。所以——這些確實是毛利率擴張的主要驅動因素。在我們進入 Mike 問題的另外兩個部分之前,Rob,你是否想補充什麼?

  • Rob Davis - CFO

    Rob Davis - CFO

  • No, I think --

    不,我想——

  • Bob Parkinson - CEO

    Bob Parkinson - CEO

  • Why don't you address the buy-back question and also the CapEx.

    不如你來回應回購問題,以及資本支出(CapEx)。

  • Rob Davis - CFO

    Rob Davis - CFO

  • Sure. Actually, Mike, we're assuming on a net basis $750 million of purchases. So it could be just in the way you are phasing those, but that's currently what we're operating to, and obviously, as we move through the year, that's something we will continue to evaluate, as we did in 2008. With regard to the capital expenditures, the $1 billion is really a good story, and what it really tells you is that as we continue to become more confidence in the continued growth of our business, as we continue to see the need for capacity expansion across all of the businesses, and to invest in our R&D infrastructure, that's lead us to increase investments from where we originally expected.

    好的。其實,Mike,我們假設以淨額計算回購 7.5 億美元。所以可能只是你在分期(phasing)上的方式不同,但這是我們目前的運作假設;當然,隨著年度推進,這也是我們會持續評估的事項,就像我們在 2008 年所做的一樣。至於資本支出,10 億美元其實是一個好故事;它真正告訴你的是,隨著我們對業務持續成長更有信心,並且持續看到各項業務都有擴充產能的需求,以及需要投資我們的研發基礎設施,這些都促使我們把投資提高到原先預期之上。

  • I would point out that it's not due to programs which are costing more or being significantly extended in time. It is truly due to the fact that we (inaudible) capital investment opportunities to drive growth, more than we expected. So that's really what's behind the $1 billion.

    我想指出,這並不是因為某些計畫成本上升或時程被大幅延長。這確實是因為我們(聽不清)資本投資機會以推動成長,超出我們原先的預期。所以這就是 10 億美元背後的原因。

  • Mike Weinstein - Analyst

    Mike Weinstein - Analyst

  • One follow-up then I'll let others jump in here. Bob, you grew organically 9% on the top line this quarter, which was obviously a very strong quarter for Baxter and you are guiding at a starting point of 7% for 2009. It would -- it would certainly appear and the street's assumption that the economy is not having a significant impact on our your business. Are there any touch points that we should be watching as you move through 2009? And how good is your visibility relative to your different businesses right now? Thanks.

    我再追問一個問題,然後讓其他人加入。Bob,你們本季營收有機成長 9%,這顯然是 Baxter 非常強勁的一季;而你們對 2009 年的指引起點是 7%。這——這看起來也符合市場的假設:經濟對你們的業務似乎沒有造成顯著影響。當你們在 2009 年推進時,有哪些我們應該觀察的接觸點(touch points)?以及就你們不同業務而言,目前你們的能見度有多好?謝謝。

  • Bob Parkinson - CEO

    Bob Parkinson - CEO

  • Yeah, there's a lot there. Let me try to be pretty succinct here. First of all the 9% was benefited -- benefited to some degree based on vaccine sales and -- in the fourth quarter, but I think if you look over the last year or two, we have pretty consistently when you adjust for FX, the TT divestiture, the BeneFIX loss and so on, been running organic growth around the 8% range. Our organic projection -- growth projection for next year as Rob mentioned is 7%, candidly, that reflects some modest impact to, really, the potential impact of the global economic environment in which we operate. Nobody has a crystal ball. I mean, we think we are very well positioned because of the medically necessary nature of our products.

    是的,這裡面有很多內容。我盡量簡潔。首先,這 9% 在某種程度上受益——受益於疫苗銷售,以及——在第四季;但我認為如果你回看過去一兩年,當你調整外匯、TT 出售(divestiture)、BeneFIX 流失等等因素後,我們的有機成長相當一致地大約落在 8% 左右。正如 Rob 提到的,我們對明年的有機成長預測是 7%;坦白說,這反映了我們所處的全球經濟環境可能帶來的一些溫和影響。沒有人有水晶球。我是說,我們認為自己處於非常有利的位置,因為我們產品具有醫療必要性。

  • Frankly, people are not going to go off of dialysis therapy or therapy for hemophilia or immune disorders because of the economy. I would say that if you look at our medication delivery business, we know that many hospitals are experiencing a softening in hospital admissions to some degree surgical procedures, frankly whether or not those are procedures that consume IV solutions to a great degree and so on, we don't really know, and through the fourth quarter, we haven't really experienced anything, but we thought it prudent as we pulled together our plan for next year, to reflect something there, but I think we have pretty high confidence level that we can deliver the 7% organic growth. The other things in the economy, since you raised it, and this is probably a basis for other follow-on questions so we ought to address it at the outset, we do believe we will be begin experiencing some DSO deterioration because of the economic environment in 2009, although interestingly in the fourth quarter we had our best DSO quarter in a long time, including in the US, so go figure.

    坦白說,人們不會因為經濟因素就停止透析治療,或停止血友病或免疫疾病的治療。我會說,如果你看我們的藥物輸送業務,我們知道許多醫院在住院收治方面在某種程度上出現趨緩,外科手術程序也是如此;坦白說,這些是否屬於大量消耗靜脈注射(IV)溶液的程序等等,我們其實不太清楚。而在第四季期間,我們並沒有真正感受到任何影響,但在我們彙整明年計畫時,我們認為審慎起見應在那裡反映一些因素。不過我認為,我們對於能夠達成 7% 的有機成長有相當高的信心。你既然提到經濟,其他方面——這也可能是後續其他追問的基礎,所以我們一開始就應該先處理——我們確實相信,因 2009 年的經濟環境,我們將開始經歷一些 DSO(應收帳款週轉天數)惡化;但有趣的是,第四季我們的 DSO 是很長一段時間以來表現最好的一季,包括在美國也是如此,所以你說怪不怪。

  • In terms of emerging and developing markets as their healthcare budgets get scrutinized, perhaps reduced to some degree, we may be experiencing some impact on lower volumes and access to some of the tenders, although as of yet we haven't seen that. And, of course, the other practical area that hospitals are dealing with particularly in the US because of cash constraints and liquidity constraints, and so on, is CapEx spending, and, as we have very little that really is impacted by that, a bit of an irony it may even serve to secure our Colleague base longer and the (inaudible) erosion experienced over the last couple of years. . So I I'll stop there. There may be some specific follow ups to that Mike, but I'll just conclude

    就新興與開發中市場而言,當它們的醫療保健預算受到更嚴格的審視、或可能在某種程度上被削減時,我們可能會在較低的出貨量以及取得部分標案(tenders)的可及性方面受到一些影響,儘管截至目前我們尚未看到這種情況。當然,另一個醫院正在面對的實務面——特別是在美國,因為現金與流動性限制等等——是資本支出(CapEx)支出;而由於我們真正受其影響的部分很少,具有一點諷刺意味的是,這甚至可能讓我們的 Colleague 裝機基礎維持更久,並減緩過去幾年所經歷的(聽不清)侵蝕。所以我就先說到這裡。Mike,可能會有一些具體的追問,但我先做個結語。

  • Mike Weinstein - Analyst

    Mike Weinstein - Analyst

  • Perfect. Thanks for taking my question.

    很好。謝謝你回答我的問題。

  • Mary Kay Ladone - VP Investor Relations

    Mary Kay Ladone - VP Investor Relations

  • Hey, Mike, it is Mary Kay too, I would also like to add to Bob's comments in terms of the sales growth guidance.. One thing we didn't mention in our prepared comments is that transfusion therapy sales will be declining in 2009 to be about $50 million for the full year. That's versus 2008 of about $170 million, so that also has about a 1% impact on our overall sales growth.

    嗨,Mike,我是 Mary Kay,我也想就銷售成長指引補充 Bob 的評論。我們在事先準備的發言中沒有提到的一點是:輸血治療(transfusion therapy)銷售在 2009 年將下滑,全年約為 5,000 萬美元。相較之下,2008 年約為 1.7 億美元,因此這也會對我們整體銷售成長造成約 1% 的影響。

  • Mike Weinstein - Analyst

    Mike Weinstein - Analyst

  • Yeah. Great. Okay? Next?

    是的。很好。好嗎?下一位?

  • Operator

    Operator

  • Thank you. Our next question, Rick Wise of Leerink Swann is on the line.

    謝謝。下一個問題,Leerink Swann 的 Rick Wise 在線上。

  • Rick Wise - Analyst

    Rick Wise - Analyst

  • Good morning, everybody. Bob let me talk about a strategic issue first. Acquisitions, I think have been on your mind from the beginning as a potential growth driver. Couple of parts. Do you think the environment is more attractive? Is Baxter now more likely, given what should be better pricing and availability? Are you more inclined or less inclined now in the next 12 months if there are any areas you want to highlight be happy to hear that as well.

    各位早安。Bob,我先談一個策略性議題。併購,我想從一開始你們就把它視為潛在的成長驅動因素之一。我有幾個部分想問。你認為現在的環境更具吸引力嗎?鑑於應該會有更好的價格與可取得性,Baxter 現在是否更可能出手?在未來 12 個月你們會更傾向或較不傾向進行併購?如果有任何你想特別強調的領域,也很樂意聽聽。

  • Bob Parkinson - CEO

    Bob Parkinson - CEO

  • Sure. Thanks, Rick. First of all, let me say this, if you look back over the last several years, of course, you know, our BD activities have been limited largely to licensing acquiring smaller products that are complementary and so on, but I think our strategy of focusing internally on really extracting value that exists in our existing core businesses has proven to be the right strategy. Given our improved financial results. And not distracting the organization to acquisitions and -- and so on.

    當然。謝謝你,Rick。首先我想說,如果你回顧過去幾年,當然你知道,我們的 BD(業務開發)活動大多侷限於授權、收購一些互補性的小型產品等等;但我認為,我們把策略聚焦在內部、真正把既有核心業務中存在的價值挖掘出來,已被證明是正確的策略。鑑於我們改善的財務成果,也避免讓組織因併購而分心——等等。

  • I would say that while there continues to be great opportunity for growth margin expansion going forward in our existing businesses we're in a position now as a company both in terms of our improved financial position over the last few years, and I also think importantly, our organizational capabilities to now be a bit more expansive in evaluating opportunities, and perhaps bringing things in, including acquisitions, and it is happening at a time, whereas you pointed out -- or referenced, Rick, in your question -- the environment is -- or implied in your question -- the environment is such that there may be -- it may be a more target-rich environment right now, and so clearly we're very open minded to that, but we're also very cognizant of our need to be disciplined and not do deals for the sake of doing deals, but doing deals that we are confident will create value for our shareholders. We have our BD teams evaluating opportunities, we're looking at it. Like I said, we have the financial wherewithal and now the organizational wherewithal to perhaps do some things, and you all will be the first to know.

    我會說,雖然我們既有業務在未來仍有很大的成長與毛利擴張機會,但我們公司現在的處境——不論是過去幾年改善的財務狀況,還有我認為同樣重要的,我們的組織能力——都讓我們可以在評估機會時更為開放,並可能把一些東西納入,包括併購。而這也發生在一個時點:正如你在問題中指出——或提到——的,環境(或你問題中暗示的)可能使得現在成為一個標的更充沛的環境,因此我們顯然對此非常開放,但我們也非常清楚必須保持紀律,不是為了做交易而做交易,而是要做我們有信心能為股東創造價值的交易。我們的 BD 團隊正在評估機會,我們也在看。就像我說的,我們具備財務實力,現在也具備組織上的能力,或許可以做一些事情,而你們也會是第一批知道的人。

  • Rick Wise - Analyst

    Rick Wise - Analyst

  • Okay, sounds good. The -- on Colleague, you highlighted that you are not assuming everything gets resolved this year. What is left to resolve if it's worth discussing? On the competitive front there has been some major GPO contract wins for one of your competitors. And maybe just the last part of that, if Colleague were to come back -- can you help us think what that might mean for any given quarter or any 12-month period, (inaudible) just to put things in perspective sort of year one of the resolution of this situation?

    好的,聽起來不錯。關於 Colleague,你提到你們並未假設今年所有事情都能解決。若方便討論,還有哪些事項尚待解決?在競爭面上,你們某個競爭對手在一些主要的 GPO 合約上有重大斬獲。最後一部分,如果 Colleague 回歸——你能否協助我們思考,這對任何單一季度或任何 12 個月期間可能意味著什麼,(聽不清)只是為了把事情放在脈絡中,算是這個情況解決後的第一年?

  • Bob Parkinson - CEO

    Bob Parkinson - CEO

  • Yeah, first of all, Rick, relative to the GPO situation, I'm not sure that any of our competitors have carved out a unique position with any GPO that is really created an obstacle for us, or a barrier in terms of Colleague going forward. There have been GPOs that have made multiple awards to all suppliers, but it doesn't necessarily close the door to us, so I think it's important to clarify that at the outset. If you hearken back to the time when we were commercializing Colleague in the US, we were generating roughly $150 million of sales associated with placement of hardware in any given year. That does not include, of course, the disposable trail that's associated with that, so that's probably the best kind of high-level number I can give you in response to when we get back in a position where we can recommercialize what one might expect on an annual basis.

    是的,首先,Rick,關於 GPO 的情況,我不確定我們任何競爭對手是否在任何 GPO 上取得了真正獨特的地位,從而對我們、或對 Colleague 未來造成障礙或壁壘。有些 GPO 對所有供應商都做了多重授標,但這不一定會把我們拒之門外,所以我認為一開始先澄清這點很重要。如果你回想我們在美國商業化 Colleague 的時期,我們在任何一年與硬體裝機相關的銷售額大約是 1.5 億美元。當然,這不包含與之相關的一次性耗材(disposable)後續銷售,所以這大概是我能給你的最佳高層次數字,用來回應當我們回到可以重新商業化時,年度層面可能會期待什麼。

  • I suppose one could also suggest that there may be some pent-up demand in accounts that have not been able to buy Colleague, but hopefully at some point will be able to. But I don't really want to speculate what that might be. But that's kind of an order of magnitude response.

    我想也有人會認為,在那些一直無法購買 Colleague 的客戶中,可能存在一些被壓抑的需求,但希望在某個時間點能夠購買。不過我不太想推測那會是多少。但這就是一個量級上的回答。

  • Rick Wise - Analyst

    Rick Wise - Analyst

  • Last quick one. When should we expect to see the Phase III, IGIV data, and if there are any other indications on the growing clinical trials and market opportunities that might pop up through the year? Thank you.

    最後一個快問:我們何時應該期待看到第三期(Phase III)的 IGIV 數據?另外,今年是否還會有其他適應症、正在擴大的臨床試驗與市場機會可能浮現?謝謝。

  • Bob Parkinson - CEO

    Bob Parkinson - CEO

  • Are you referring to Rick on the first part -- Alzheimer's?

    Rick,你第一部分指的是——阿茲海默症嗎?

  • Rick Wise - Analyst

    Rick Wise - Analyst

  • I'm sorry, yes.

    抱歉,是的。

  • Bob Parkinson - CEO

    Bob Parkinson - CEO

  • Why don't you go through the Alzheimer's as well as some of the other Phase III initiatives.

    那你不妨談談阿茲海默症,以及其他一些第三期(Phase III)計畫。

  • Mary Kay Ladone - VP Investor Relations

    Mary Kay Ladone - VP Investor Relations

  • On Alzheimer's, Rick, we just started the Phase III. That is an 18-month trial with 360 patients. We're anticipating right now about 12 months for the patient enrollment. And we will not have an interim look at that data. So it's going to be a couple of years before you see any Phase III results on the Alzheimer's trial. You will see, though, in 2009, the Phase II, 18-month results, and at this point in time, we -- we can't give you a time frame for that. That's really being handled by Dr. Ralph Gannon, and when he decides on his opportunity to present that information we will let you know where that will be and when that will be. We also have ongoing -- as Bob mentioned earlier in his comments -- a Phase III for MMN, and that's about a 40-patient trial. 15 months follow-up, so that probably -- you won't see anything until 2010 on MMN.

    關於阿茲海默症,Rick,我們剛啟動第三期。那是一個 18 個月的試驗,納入 360 名病患。我們目前預期病患入組大約需要 12 個月。而我們不會對該數據做期中分析(interim look)。所以在你看到阿茲海默症第三期結果之前,還需要幾年。不過,你會在 2009 年看到第二期(Phase II)的 18 個月結果;但就目前而言,我們——我們無法給你時間表。這主要由 Ralph Gannon 醫師負責,當他決定在何時、何地發表這些資訊時,我們會告訴你會在哪裡以及何時。我們也有持續進行——如 Bob 先前在評論中提到——針對 MMN 的第三期試驗,約 40 名病患。追蹤 15 個月,所以 MMN 方面你大概要到 2010 年才會看到任何結果。

  • Rick Wise - Analyst

    Rick Wise - Analyst

  • Thanks very much.

    非常感謝。

  • Bob Parkinson - CEO

    Bob Parkinson - CEO

  • How about Enhanze?

    那 Enhanze 呢?

  • Mary Kay Ladone - VP Investor Relations

    Mary Kay Ladone - VP Investor Relations

  • And also we did start as Bob mentioned the Phase III IGIV trial combined with Enhanze, the -- Halozyme technology, and I know that is also a 12 month trial, so that, . again, that will be 2010 before you see any

    另外,如 Bob 提到的,我們也已啟動第三期 IGIV 試驗,並與 Enhanze 結合,也就是 Halozyme 的技術;我知道那同樣是一個 12 個月的試驗,所以——同樣地——在你看到任何結果之前會是 2010 年。

  • Rick Wise - Analyst

    Rick Wise - Analyst

  • Okay. Appreciate it.

    好的。感謝。

  • Mary Kay Ladone - VP Investor Relations

    Mary Kay Ladone - VP Investor Relations

  • Next question?

    下一個問題?

  • Operator

    Operator

  • Bruce (inaudible) is on the with UBS. Please state your question.

    UBS 的 Bruce(聽不清)在線上。請提出你的問題。

  • Unidentified Participant

    Unidentified Participant

  • Thank you. Lots of clients have expressed concerns to us regarding the fact that the economy is bringing more people in to the plasma collection centers. Clearly, your ability to take price in plasma products, and we're estimating almost 10% this year, suggests to us that the supply/demand balance is just fine for IVIG in particular. Could you comment on the -- that phenomena with regards to drawing people in the collection centers, and, what the kind of relative rates of intrinsic demand versus supply might be for IVIG globally? Thank you.

    謝謝。許多客戶向我們表達擔憂,認為經濟情勢正把更多人帶進血漿採集中心。顯然,您在血漿產品上的提價能力——我們估計今年接近 10%——讓我們覺得供需平衡,特別是針對 IVIG,應該是相當良好。您能否評論一下——關於吸引更多人到採集中心捐漿的這個現象,以及就全球 IVIG 而言,內生需求相對於供給的相對增速大概會是什麼樣子?謝謝。

  • Bob Parkinson - CEO

    Bob Parkinson - CEO

  • Yeah, Bruce, this is Bob. Let me start and then maybe Rob or Mary Kay could support my comments. First of all I don't believe the number of people coming forward willing to donate plasma has any impact relative to the overall supply. The supply is a function of installed capacity, which as you pointed out, and we continue to believe is well balanced with demand. If anything I suppose it it might imply over time, cost of selecting plasma may go down, although we haven't experiences that to date. I don't see that phenomenon, in other words more people presenting at the plasma center to donate plasma and getting paid to do that as really a relevant variable in terms of the supply equation. (inaudible)

    是的,Bruce,我是 Bob。我先說,然後也許 Rob 或 Mary Kay 可以補充。首先,我不認為願意出來捐血漿的人數增加,會對整體供給造成任何影響。供給取決於已裝設的產能;正如你指出的,我們也持續相信供給與需求之間是相當平衡的。若真要說,長期來看它或許意味著篩選血漿的成本可能會下降,雖然到目前為止我們還沒有看到這種情況。我不認為這個現象——換句話說,更多人到血漿中心捐血漿並因此獲得報酬——在供給方程式上是一個真正相關的變數。(聽不清)

  • Rob Davis - CFO

    Rob Davis - CFO

  • Yeah, I would just add, it is important -- because we have gotten this question a lot -- it's important to understand that the bottleneck today in the supply side of the equation is the collection capacity in the industry. So -- so if you are running your censer at capacity, which we largely are. We have been able over 2008 to do a great job, frankly, our bio (inaudible) have done a great job of squeezing additional yields from our existing footprints. But once you reach capacity in the center, the number of people presenting doesn't change the capacity of the people you can move through. That's why we continue to believe this has not had any impact on total collections.

    是的,我只想補充一點,這很重要——因為我們被問到很多次——要理解的是,今天供給端的瓶頸在於產業的採集產能。所以——如果你的中心是在滿載運轉,而我們大致上就是如此。我們在 2008 年能做到非常好,坦白說,我們的生物(聽不清)在既有據點上擠出了更多的產出。但一旦中心達到產能上限,到場的人數並不會改變你能處理的人流量。這就是為什麼我們仍然相信,這對總採集量沒有造成任何影響。

  • I think to Bob's point, it continues to cause you to rethink, how do you price the collections? How do you market for collections? The other thing I would note that where you have seen some is there's -- at least anecdotally, we have heard there is a reduction in people donating plasma -- free plasma, if you will, whole blood to the American Red Cross, and similar organizations in hopes of trying to do it to a fee-based center. But, again, if the capacity is limited that will change the total numbers. On the second part of your question, we continue long term to believe we are going to see from a total market perspective, growth in volume, mid-to high single digits, and growth in price of low to mid-single digits longer term. We did better than that in both categories in 2008, and we will see how it plays out during 2009. I think the important thing here -- and we have talked a lot about this externally, is really to understand the demand side of this picture. We are increasingly confident in the robustness and sustainability of the demand.

    我認為就 Bob 的觀點而言,這確實會讓你重新思考:你要如何為採集定價?如何行銷以取得採集量?另外我想指出的是,你確實看到一些情況——至少從軼聞來看,我們聽說有些人減少捐血漿——如果你願意稱之為「免費血漿」——也就是捐全血給美國紅十字會及類似組織,而希望改去收費型中心捐贈。但同樣地,如果產能受限,這不會改變總量。至於你問題的第二部分,我們長期仍然相信,從整體市場角度來看,量的成長會在中到高個位數,而價格的成長長期會在低到中個位數。2008 年我們在這兩個類別都做得更好,2009 年會如何發展我們再觀察。我認為這裡重要的是——我們對外談了很多——真正要理解的是需求端。我們對需求的強韌性與可持續性愈來愈有信心。

  • As you heard we're driving new indications. We're seeing favorable demographics, so all of the factors are really driving the demands stronger, and to us that's the real key, now all we have to do as an industry is make sure we keep supply up with demand, keep it in balance, and we're confidence we can do that. No change in our view of stability. No change in what we see as collection growth. It's steady as she goes.

    如你所聽到的,我們正在推動新的適應症。我們也看到有利的人口結構,因此所有因素都在推動需求更強,而對我們而言這才是關鍵。現在產業要做的就是確保供給跟上需求、維持平衡,而我們有信心能做到。我們對穩定性的看法沒有改變;對採集成長的觀察也沒有改變。就是穩穩地往前走。

  • Unidentified Participant

    Unidentified Participant

  • Terrific, and just one follow-up, can you talk a bit about the dynamics you see in the dialysis segment next year, and how you arrived at -- I guess mid-single-digit growth in PD?

    太好了,另外再追問一題:你能談談你對明年透析(dialysis)領域的動態觀察,以及你們是如何得出——我想是 PD 中個位數成長——這個判斷的嗎?

  • Bob Parkinson - CEO

    Bob Parkinson - CEO

  • Sure. This is Bob, Bruce. I -- probably -- I would differentiate the US market versus, let's say emerging developing markets, which continue as we commented, and as you know to be the primary driver for growth. The most significant event that transpired in the US in 2008, of course, was a -- Medicare legislation that relates to both patient education, to -- to ensure that all patients that need to be treated are aware of the various therapies that are available, including PD. That has not been the case, and that is going to be required in 2010.

    當然。Bruce,我是 Bob。我——可能——會把美國市場與例如新興發展中市場區分開來;正如我們評論過、你也知道的,新興發展中市場仍是成長的主要驅動力。2008 年在美國發生的最重要事件,當然是——與 Medicare 相關的立法,涉及病患教育——以確保所有需要治療的病患都了解可用的各種療法,包括 PD。過去並非如此,而這將在 2010 年成為要求。

  • And then, of course, new reimbursement, composite rate reimbursement in 2011 -- which, frankly, we believe will level the playing field in terms of the economics-- the economic decision that -- that -- or that comes in to play in terms of selecting therapy, HD or PD, so we think these are external events that will set the stage for enhanced PD growth, perhaps significantly. Let's say 2011, and beyond. So that's a very positive development. We anticipate that an emerging developing markets, China being a great example, we're going to continue to experience strong growth where many of these markets PD is much more broadly embraced than HD, and to a large degree it is because you don't have some of the economic dynamics that exist in the US market.

    然後,當然還有 2011 年的新給付制度——綜合費率(composite rate)給付——坦白說,我們相信這將在經濟面上拉平競爭環境——也就是在選擇療法(HD 或 PD)時所涉及的經濟決策,因此我們認為這些外部事件將為 PD 成長的提升奠定基礎,甚至可能相當顯著。比如說 2011 年及之後。所以這是非常正面的發展。我們預期在新興發展中市場——中國是一個很好的例子——我們將持續經歷強勁成長;在許多這類市場中,PD 的接受度遠比 HD 更廣泛,而很大程度上是因為它們不像美國市場那樣存在某些經濟動態。

  • As I referenced in my prepared comments, you've heard us say before, when presented with options of therapies, 50% of the patients in virtually every country around the world, frankly would prefer to be on home dialysis. The convenience associated with that from a cost point of view, typically delivering therapy in the home is a lower cost than in the center for -- I think some obvious reasons and finally for many patients the clinical outcomes are enhanced, and so while the last couple of years has been a challenge in our overall renal business in a number of ways, we continue to be very bullish about the long-term prospects of the renal business, and I think this is one of the areas we'll expand on in our September investor's conference to give you a little bit more incite as to the basis of our confidence in the years ahead.

    如我在事先準備的評論中提到的,你們以前也聽我們說過:當提供多種療法選項時,全球幾乎每個國家有 50% 的病患,坦白說,會偏好居家透析。從成本角度來看,與在中心治療相比,在家中提供治療通常成本更低——我想原因很明顯——最後,對許多病患而言,臨床結果也更好。因此,雖然過去幾年我們整體腎臟(renal)業務在多方面都面臨挑戰,我們仍然非常看好腎臟業務的長期前景。我想這也是我們在 9 月投資人會議上會進一步說明的領域之一,讓你更深入了解我們對未來幾年信心的基礎。

  • Unidentified Participant

    Unidentified Participant

  • Thanks so much.

    非常感謝。

  • Operator

    Operator

  • David Roman of Morgan Stanley is on the line with a question. Please state your question.

    Morgan Stanley 的 David Roman 在線上要提問。請提出你的問題。

  • David Roman - Analyst

    David Roman - Analyst

  • Good morning.

    早安。

  • Bob Parkinson - CEO

    Bob Parkinson - CEO

  • Good morning.

    早安。

  • David Roman - Analyst

    David Roman - Analyst

  • One follow-up question on demand for Rob's comments and two questions on investment maybe for Bob. Rob, you mentioned a driver being the demand side not the supply side. Obviously emerging markets have been a component of that. It looked like international growth in some of the biosciences units was weaker in the fourth quarter, obviously not carrying forward in your '09 guidance, but can you comment on any softness in South America, any of the Brick countries, Russia or China for the morning demand for therapeutics.

    一個追問是關於需求、呼應 Rob 的評論;另外兩個問題可能是給 Bob、關於投資。Rob,你提到驅動因素在需求端而非供給端。顯然新興市場是其中一個組成。看起來第四季某些生物科學事業單位的國際成長較弱,顯然也沒有延續到你們 2009 年的指引中;但你能否評論一下南美是否有任何疲軟,或是金磚國家(BRIC)中的俄羅斯或中國,在治療性產品的需求方面是否有任何走弱?

  • Rob Davis - CFO

    Rob Davis - CFO

  • Yeah, the short answer is we saw no softness that would be anything going on in the broader economy. It was really timing of how things moved through the quarters, and in fact in Russia as an example, we had a successful launch tender, so there's no -- you should take no sign, and I would look to our 2009 guidance as confidence of that.

    是的,簡短回答是:我們沒有看到任何可歸因於整體經濟的疲軟。那主要是季度之間推進節奏的時間差;事實上,以俄羅斯為例,我們成功完成了一次上市招標,所以沒有——你不應該從中解讀出任何訊號;我會請你看我們 2009 年的指引,這就是我們的信心所在。

  • Mary Kay Ladone - VP Investor Relations

    Mary Kay Ladone - VP Investor Relations

  • Yeah, I would also, David, remind you, that we talked about this back in Q3-10. We had most of our tenders in Q3 this year, and last year they were in Q4, so we had a really difficult comp across the plasma protein in 2008 in the fourth quarter.

    是的,David,我也提醒你,我們在 Q3-10 就談過這件事。今年我們大部分的招標在第三季,而去年是在第四季,所以 2008 年第四季在血漿蛋白業務上,我們面臨非常困難的同比比較。

  • David Roman - Analyst

    David Roman - Analyst

  • Okay. Very helpful. And maybe Bob, two questions on investment. First on capital spending. Obviously close to $1 billion this year. When you think about the level of your investment, you think into the out years in 2010 and beyond. Is this level of investment in manufacturing and fractionation give you the confidence that perhaps in a pricing environment that is less favorable in 2010 and beyond, these type of investments are going to enable you to still increase gross margins at the kind of rates we've seen historically of 100 to 150 BIPs a year.

    好的。非常有幫助。那麼 Bob,關於投資我有兩個問題。第一個是資本支出。顯然今年接近 10 億美元。當你思考投資水準、放眼 2010 年及之後的年度時,這種在製造與分離(fractionation)上的投資水準,是否讓你有信心:即使 2010 年及之後的定價環境不那麼有利,這類投資仍能讓你把毛利率以我們歷史上看到的那種速度——每年 100 到 150 個基點——持續提高?

  • Bob Parkinson - CEO

    Bob Parkinson - CEO

  • I don't think-- regarding the second part of your question, given the fairly dramatic ramp up in plasma pricing, if you go back over the last couple of years, while we're confident in our ability to deliver low to mid-single-digit price increase going forward, because they are not going to be the same degree going forward as in the past, that particular dynamic will have kind of a modulating effect, but I would say relative to CapEx spending, you can expect that kind of $1 billion range going forward. I'm hopeful that that's the case because as Rob pointed out earlier, this is an investment largely in capacity to support, not only volume growth of existing businesses, but new indications for products and new products and so on. So I would expect that around this level -- maybe not every year, but I think, really, our annual spending on CapEx has ramped up, but I think it is a good news story, and we would anticipate that is going to be continue.

    我不認為——就你問題的第二部分而言,考量到過去幾年血漿價格相當劇烈的上升,如果你回頭看,雖然我們對未來持續實現低到中個位數的價格上漲有信心,但由於未來不會像過去那樣大幅度上漲,這個動態會產生某種程度的調節效果。不過就資本支出而言,你可以預期未來仍會在約 10 億美元這個區間。我希望會是如此,因為如 Rob 先前指出,這些投資主要是投向產能,以支援不僅是既有業務的量成長,也包括產品的新適應症、新產品等等。因此我預期大致會維持在這個水準——也許不是每一年都一樣,但我認為我們每年的資本支出確實已經拉升,而我認為這是一個好消息的故事,我們也預期這將會持續。

  • David Roman - Analyst

    David Roman - Analyst

  • Okay, and the second major investment obviously would be in R&D and I wonder if you think about the growth trajectory of your three major business units, and think about your relative level of R&D across this,you get into the aggression of the pipeline in its various segments, I wonder if you could tell us kind of right now, where you are feeling more comfortable, and where you are feeling less comfortable.

    好的,第二項主要投資顯然會在研發(R&D)上。我想請教您,當您思考三大事業單位的成長軌跡,以及各事業相對的研發投入水準時,進一步看各個區隔的產品管線推進強度(aggression),您能否談談目前哪些地方讓您覺得比較安心,哪些地方讓您覺得比較不安心?

  • Bob Parkinson - CEO

    Bob Parkinson - CEO

  • I think we have great pipeline opportunities in all three of our businesses, and I won't take the time this morning to enumerate those, having said that we have ramped up our R&D investment in bioscience at a faster rate than the other businesses, and I think for some fairly obvious reasons. I think one of these I'm most pleased about as I reflect back on the last four or five years, is that as a result of our improving financial performance, we have been able to fund a fairly dramatic ramp up in R&D, and the nature of our pipeline has changed.

    我認為我們三個事業都有很好的產品管線機會,今天早上我就不花時間逐一列舉了。不過,我們確實以比其他事業更快的速度提高了生物科學(bioscience)的研發投資,我想原因相當明顯。回顧過去四、五年,我最滿意的一點是:由於我們財務表現改善,我們得以支應研發的大幅加碼,而我們的產品管線性質也因此改變。

  • Because if you go back five years ago, most of the stuff was near-term kind of opportunistic kinds of programs, and today we have a great balance of, yes, some of those kinds of programs, but things more of a pharmaceutical nature, largely in our bioscience business, which are longer term R&D programs, may have a higher element of risk but of course, the payback intended with that is higher, so and again as we mentioned in the prepared comments, we're projecting again in '09 to grow R&D at a faster rate than top-line organic growth, which is a strategic priority for the company. But, again, on this whole R&D question, it will be one of the primary areas of focus in our September investor conference, because we realize, we haven't been terribly detailed on the pipeline, and that will provide an opportunity, I think to be a little more explicit than we have been in the past.

    因為如果回到五年前,多數專案都是偏近期、較具機會型(opportunistic)的計畫;而今天我們有很好的平衡:是的,仍有一些那類計畫,但也有更多偏藥品(pharmaceutical)性質的項目,主要在我們的生物科學事業中,屬於較長期的研發計畫,風險成分可能更高,但當然預期的回報也更高。再者,如同我們在事先準備的評論中提到的,我們預期在2009年('09)研發成長率仍將高於營收端的有機成長,這是公司的策略優先事項。不過,關於整體研發的問題,這將是我們9月投資人會議的主要焦點之一,因為我們也知道過去對產品管線的說明不夠細,屆時我想會是個機會,讓我們比以往更明確一些。

  • David Roman - Analyst

    David Roman - Analyst

  • Okay, thank you very much.

    好的,非常感謝。

  • Bob Parkinson - CEO

    Bob Parkinson - CEO

  • Yep.

    是。

  • Operator

    Operator

  • Benjamin Andrew of William Blair is on the line with a question. Please ask your question.

    William Blair 的 Benjamin Andrew 在線上提問。請提出您的問題。

  • Benjamin Andrew - Analyst

    Benjamin Andrew - Analyst

  • Good morning, just wanted to follow up on one quick question. You mentioned during the discussion about delivery that you saw some lower access set sales in the quarter. Was there something unusual there, or is that something we should be keeping an eye on a little more closely for '09 as well?

    早安,我想追問一個簡短問題。您在談到輸注(delivery)時提到,本季看到 access set 的銷售較低。那裡是否有什麼不尋常的情況?或者這也是我們在2009年('09)需要更密切留意的事情?

  • Mary Kay Ladone - VP Investor Relations

    Mary Kay Ladone - VP Investor Relations

  • You know, Ben, I'm looking at that, really, from a dollar perspective, wasn't real material, but the sales level in that business is so small that a small amount reflects a larger percentage, so I think we were down 3, 4, $5 million in the quarter.

    Ben,你知道的,我從金額角度看,那其實不算很重大;但那個業務的銷售基數很小,所以小幅變動就會反映成較大的百分比。我想我們本季大概少了3、4、500萬美元。

  • Benjamin Andrew - Analyst

    Benjamin Andrew - Analyst

  • Oh, okay.

    喔,了解。

  • Bob Parkinson - CEO

    Bob Parkinson - CEO

  • The other thing, let me just add to that just to be very direct, because that's associated with Colleague placements, and Colleague channels, we saw no meaningful deterioration in the fourth quarter of our channel base. So if you see that softness in access sales don't conclude that's because our channel base or Colleague in the US declined dramatically, it did not. It really is more of a quarterly dynamics. Given the smaller numbers and the percentages and so on (inaudible).

    另外我再補充一下,直接說明:那與 Colleague 的裝機(placements)以及 Colleague 通路有關。我們在第四季並未看到通路基礎有任何實質惡化。所以如果你看到 access 銷售偏軟,不要就此推論是因為我們在美國的通路基礎或 Colleague 大幅下滑;並沒有。這比較是季度性的波動。由於數字較小、百分比等因素(聽不清楚)。

  • Benjamin Andrew - Analyst

    Benjamin Andrew - Analyst

  • Okay, and one other question on anesthesia. You talked about continued geographic expansion. If either -- maybe roll us through some of the particular countries you going after, or if another way to look at it is kind of percentage of opportunity that's being opened up in '09, and is there a material amount more or less for 2010 and beyond to kind of sustain that anesthesia growth.

    好的。關於麻醉(anesthesia)我還有一個問題。您談到持續的地理擴張。您是否可以帶我們看一下你們鎖定的一些特定國家?或者換個角度,2009年('09)將開拓的機會大概占比多少?以及2010年及之後是否還有相當多(或更多/更少)的空間,以支撐麻醉業務的成長?

  • Bob Parkinson - CEO

    Bob Parkinson - CEO

  • Let me comment maybe on the second part of the question, first, Ben. Yeah, there is material opportunity for growth throughout the LRP, which is why we describe anesthesia as a strategic business for Baxter. We are the only company that has the full array of inhalation agents. It's not a therapeutic area where the current products that are used are being obsoleted by next generation technology, so it's a great example of our global position, geographic expansion, as healthcare budgets grow around the world, surgery procedures developing in emerging markets grow at a faster rate. We're going to be there very well positioned with the full line of products to participate in that growth, so this is a long term -- this is a long-term strategic business and priority for Baxter. In terms of -- the first part of your question, markets we're going to expand in, I don't want to really get into detail of that --

    Ben,我先回應你問題的第二部分。是的,在整個長期規劃期(LRP)中都有實質的成長機會,這也是我們把麻醉描述為 Baxter 策略性業務的原因。我們是唯一一家擁有完整吸入性麻醉劑(inhalation agents)產品組合的公司。這也不是一個現有產品會被下一代技術快速淘汰的治療領域,因此它很好地展現了我們的全球地位與地理擴張:隨著全球醫療預算成長、以及新興市場的手術量以更快速度增加,我們將以完整產品線在那裡占據非常有利的位置,參與這波成長。所以這是一個長期——這是一個 Baxter 的長期策略性業務與優先事項。至於你問題的第一部分,我們將在哪些市場擴張,我不太想深入細節——

  • Rob Davis - CFO

    Rob Davis - CFO

  • I think competitive reasons, we don't want to get in to announcing --

    我想基於競爭因素,我們不想去宣布——

  • Bob Parkinson - CEO

    Bob Parkinson - CEO

  • Yeah, good idea.

    是的,好主意。

  • Benjamin Andrew - Analyst

    Benjamin Andrew - Analyst

  • Okay. That's all I had, thank you.

    好的。我就這些,謝謝。

  • Bob Parkinson - CEO

    Bob Parkinson - CEO

  • Okay. Ben. Thanks.

    好的。Ben,謝謝。

  • Mary Kay Ladone - VP Investor Relations

    Mary Kay Ladone - VP Investor Relations

  • Great. We have time for one more question.

    很好。我們還有時間再接一個問題。

  • Operator

    Operator

  • Kristen Stewart of Credit Suisse is on the line.

    Credit Suisse 的 Kristen Stewart 在線上。

  • Kristen Stewart - Analyst

    Kristen Stewart - Analyst

  • Thanks for taking my question. I was wondering if you could help give us a sense in terms of maybe some of the bioscience products, what percentage would Medicaid be a payer? And are you at all concerned about what some of the reimbursement could look like as states come under increasing financial pressure, and whether or not in this more difficult time, you might see any changes to maybe some of the (inaudible)

    謝謝讓我提問。我想請您協助我們了解一下,就某些生物科學產品而言,Medicaid 作為付款方(payer)的比例大概是多少?另外,當各州面臨愈來愈大的財務壓力時,您是否擔心給付(reimbursement)可能會變成什麼樣子?以及在這段較艱困的時期,您是否可能看到(聽不清楚)出現任何變化?

  • Bob Parkinson - CEO

    Bob Parkinson - CEO

  • Sure. Let me start maybe at the high level and then Rob and Mary Kay can think about this (inaudible) We have always said that reimbursement pressures exist for our primary products in the (inaudible) including, certainly in the hemophilia sector in our bioscience business, and as you know the vast majority of those patients are not Medicare, they are Medicaid reimbursed and evaluated on a state-by-state basis. I think there is reason to think that given the economic environment, clearly those pressures are going to continue to be evolutionary , but they have existed for a long time. There are a lot of dynamics why those pressures have not manifested themselves in a more precipitous climate.

    當然。我先從較高層次談起,然後 Rob 和 Mary Kay 也可以想想要不要補充(聽不清楚)。我們一直都說,對我們主要產品而言,給付壓力確實存在於(聽不清楚)之中,當然也包括我們生物科學事業的血友病(hemophilia)領域。而如你所知,這些病患絕大多數不是 Medicare,而是由 Medicaid 給付,並且是以各州為單位來核定與評估。我認為在目前的經濟環境下,這些壓力顯然會持續以漸進(evolutionary)的方式發展;但這些壓力其實已存在很長一段時間。之所以沒有以更急遽的方式顯現,背後有很多動態因素。

  • So, again, our position would be the reimbursement pressures will continue to be evolutionary in nature. We do not see any kind of revolutionary event, necessarily, that is going to fundamentally change the slope of that line for the Medicare reimbursed products. Rob and Mary Kay, I don't know if you want to add to

    所以再說一次,我們的立場是:給付壓力將會持續以漸進的方式演變。我們不認為會出現任何所謂的革命性事件,必然會從根本上改變 Medicare 給付產品那條趨勢線的斜率。Rob、Mary Kay,我不確定你們是否要補充——

  • Rob Davis - CFO

    Rob Davis - CFO

  • Yeah, just to give you a sense for IVIG as an example, it's about 15% under Medicaid and then for our hemophilia products a a little bit higher. But both we still have a majority of our business outside of this (inaudible) to Bob's point, we see it as evolutionary. That being said, as we think about Bob's comment on the macro environment, and how we think about our 7% organic growth, obviously we have contemplated all of that, as we came up with our expectations for 2009.

    是的,舉 IVIG 為例,Medicaid 大約占 15%;而我們的血友病產品會再高一些。不過兩者而言,我們仍有多數業務是在(聽不清楚)之外。呼應 Bob 的觀點,我們認為這是漸進式的。話雖如此,當我們思考 Bob 對總體環境的評論,以及我們如何看待 7% 的有機成長時,顯然在提出 2009 年的預期時,我們已把這些因素都納入考量。

  • Kristen Stewart - Analyst

    Kristen Stewart - Analyst

  • Okay. And are you seeing anything with Wythe's launch of their new plasma (inaudible)

    好的。那麼,對於 Wythe 推出他們新的血漿(plasma)(聽不清楚),你們有看到任何影響嗎?

  • Bob Parkinson - CEO

    Bob Parkinson - CEO

  • No. It's -- we continue to believe we are very well positioned, and are very confident in our ability, and the value of our product relative to the competitors.

    沒有。——我們仍然相信我們的定位非常好,並且對我們的能力,以及相對於競爭對手我們產品的價值,非常有信心。

  • Kristen Stewart - Analyst

    Kristen Stewart - Analyst

  • Thank you very much for taking my questions.

    非常感謝回答我的問題。

  • Bob Parkinson - CEO

    Bob Parkinson - CEO

  • Thank you.

    謝謝。

  • Rob Davis - CFO

    Rob Davis - CFO

  • Thanks, Kristen.

    謝謝你,Kristen。

  • Operator

    Operator

  • Ladies and gentlemen, this concludes today's conference call with Baxter International. Thank you for participating.

    各位女士、先生,Baxter International 今日的電話會議到此結束。感謝各位參與。